These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 3067784)
1. Mutations in ras genes in myelocytic leukemias and myelodysplastic syndromes. Bartram CR Blood Cells; 1988; 14(2-3):533-8. PubMed ID: 3067784 [TBL] [Abstract][Full Text] [Related]
2. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Janssen JW; Steenvoorden AC; Lyons J; Anger B; Böhlke JU; Bos JL; Seliger H; Bartram CR Proc Natl Acad Sci U S A; 1987 Dec; 84(24):9228-32. PubMed ID: 3122217 [TBL] [Abstract][Full Text] [Related]
3. [Activation of ras oncogene in myelodysplastic syndrome and acute myelogenous leukemia]. Hirai H; Hirano N; Yazaki Y Gan To Kagaku Ryoho; 1991 Jun; 18(7):1090-7. PubMed ID: 2053767 [TBL] [Abstract][Full Text] [Related]
4. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia. Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005 [TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia. Braun T; Fenaux P Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457 [TBL] [Abstract][Full Text] [Related]
7. Expression of the interleukin 6 gene in acute myeloid leukemia and myelodysplastic syndromes: a report on 49 cases. Collyn d'Hooghe M; Fenaux P; Lantoine D; Loucheux-Lefebvre M; Kerckaert JP Nouv Rev Fr Hematol (1978); 1990; 32(3):175-7. PubMed ID: 2216700 [TBL] [Abstract][Full Text] [Related]
8. The role of ras gene mutations in myeloproliferative disorders. Liu ET Clin Lab Med; 1990 Dec; 10(4):797-807. PubMed ID: 2272174 [TBL] [Abstract][Full Text] [Related]
9. N-ras oncogene-induced gene expression in human hematopoietic progenitor cells: upregulation of p16INK4a and p21CIP1/WAF1 correlates with myeloid differentiation. Shen S; Passioura T; Symonds G; Dolnikov A Exp Hematol; 2007 Jun; 35(6):908-19. PubMed ID: 17533045 [TBL] [Abstract][Full Text] [Related]
10. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Tartaglia M; Niemeyer CM; Fragale A; Song X; Buechner J; Jung A; Hählen K; Hasle H; Licht JD; Gelb BD Nat Genet; 2003 Jun; 34(2):148-50. PubMed ID: 12717436 [TBL] [Abstract][Full Text] [Related]
11. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Damm F; Itzykson R; Kosmider O; Droin N; Renneville A; Chesnais V; Gelsi-Boyer V; de Botton S; Vey N; Preudhomme C; Clavert A; Delabesse E; Park S; Birnbaum D; Fontenay M; Bernard OA; Solary E Leukemia; 2013 Jun; 27(6):1401-3. PubMed ID: 23443343 [No Abstract] [Full Text] [Related]
12. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes]. Bock O Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608 [TBL] [Abstract][Full Text] [Related]
13. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Nakagawa T; Saitoh S; Imoto S; Itoh M; Tsutsumi M; Hikiji K; Nakamura H; Matozaki S; Ogawa R; Nakao Y Oncology; 1992; 49(2):114-22. PubMed ID: 1574246 [TBL] [Abstract][Full Text] [Related]
14. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088 [TBL] [Abstract][Full Text] [Related]
15. Mutations within the FLR exon of NF1 are rare in myelodysplastic syndromes and acute myelocytic leukemias. Ludwig L; Janssen JW; Schulz AS; Bartram CR Leukemia; 1993 Jul; 7(7):1058-60. PubMed ID: 8321021 [TBL] [Abstract][Full Text] [Related]
16. Rapid mutational analysis of N-ras proto-oncogene in hematologic malignancies: study of 77 Greek patient. Speletas M; Arvanitidi K; Tzoanopoulos D; Tsironidou V; Pardali E; Aggeli C; Tsapogas P; Kartalis G; Sideras P; Ritis K Haematologica; 2001 Sep; 86(9):918-27. PubMed ID: 11532619 [TBL] [Abstract][Full Text] [Related]
17. Possible co-existence of RAS activation and monosomy 7 in the leukaemic transformation of myelodysplastic syndromes. Stephenson J; Lizhen H; Mufti GJ Leuk Res; 1995 Oct; 19(10):741-8. PubMed ID: 7500652 [TBL] [Abstract][Full Text] [Related]
18. Absence of N-ras mutations in myeloid and lymphoid blast crisis of chronic myeloid leukemia. Watzinger F; Gaiger A; Karlic H; Becher R; Pillwein K; Lion T Cancer Res; 1994 Jul; 54(14):3934-8. PubMed ID: 8033117 [TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes: from morphology to molecular biology. Part II. The molecular genetics of myelodysplasia. Stephenson J; Mufti GJ; Yoshida Y Int J Hematol; 1993 Apr; 57(2):99-112. PubMed ID: 8494999 [TBL] [Abstract][Full Text] [Related]
20. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q). Fidler C; Watkins F; Bowen DT; Littlewood TJ; Wainscoat JS; Boultwood J Haematologica; 2004 Jul; 89(7):865-6. PubMed ID: 15257941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]